JOYN Advisors’s Travere Therapeutics TVTX Stock Holding History

JOYN Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-359	Closed	-$8K	–	1311
2018 Q4	$8K	Sell	359 -389	-52%	-$9.68K	﹤0.01%	1075
2018 Q3	$21K	Sell	748 -573	-43%	-$16.4K	﹤0.01%	674
2018 Q2	$36K	Sell	1,321 -603	-31%	-$16.1K	0.01%	491
2018 Q1	$43K	Buy	+1,924	New	+$45.8K	0.01%	497

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JOYN Advisors's TVTX Position: Q1 2019 in Review

JOYN Advisors sold out of Travere Therapeutics (TVTX) in Q1 2019, closing a stake of 359 shares — an estimated $8K sold.

JOYN Advisors first reported a position in TVTX in Q1 2018 and held it in 4 quarters. The position peaked at $43K in Q1 2018. 131 funds tracked by Wall St. Rank hold TVTX as of Q1 2019.

JOYN Advisors reported no remaining Travere Therapeutics position as of Q1 2019 after selling out during the quarter.
JOYN Advisors sold 359 Travere Therapeutics shares in Q1 2019, an estimated $8K.
JOYN Advisors first reported a position in Travere Therapeutics in Q1 2018 and held it in 4 quarters.
JOYN Advisors's Travere Therapeutics position peaked at $43K in Q1 2018.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.